Immuno-oncology
From the Journals
PD-L1 correlates with worse sporadic, hereditary ccRCC outcomes
Patients with sporadic clear cell renal cell carcinomas expressing PD-L1 had worse disease-free survival.
News
Adjunctive Promacta approved for first-line SAA
Among the patients treated at the recommended dosing schedule, the 6-month overall response rate was 79%, and the complete response rate was 44...
Conference Coverage
Early phase 2 data: Mocetinostat/durvalumab combo shows promise in mNSCLC
WASHINGTON, D.C. – Mocetinostat/durvalumab shows activity and manageable AEs in metastatic NSCLC after progression...
From the Journals
Azacitidine-nivolumab combo 'encouraging' in AML
The response rate was higher among patients who had not received prior treatment with hypomethylating agents.
News
FDA approves pembrolizumab for sorafenib-intolerant HCC patients
Approval was based on an objective response rate of 17% in KEYNOTE-224, a single-arm trial of 104 patients with hepatocellular carcinoma who were...
Conference Coverage
Adding pembrolizumab to cisplatin-based CRT shows promise in HPV+ head and neck cancers
Pembrolizumab plus cisplatin-based chemoradiotherapy shows promise for locally advanced, HPV-positive head and neck squamous cell carcinoma.
Conference Coverage
Refractory immune-mediated colitis: Fecal transplant may be the answer
WASHINGTON – FMT shows promise for the treatment of refractory immune checkpoint inhibitor–associated colitis.
Conference Coverage
Pembrolizumab extends survival of head and neck cancer
MUNICH – Pembrolizumab was associated with longer overall survival and more durable responses than was cetuximab-based chemotherapy.
Conference Coverage
Nivo + ipi shows durable activity against metastatic melanoma
MUNICH – Four-year data from the Checkmate 067 study bolster earlier findings supporting the checkpoint inhibitor combination in first line...
From the Journals
Checkpoint inhibitor doubles 3-year survival rate of BRAF wild-type advanced melanoma
The 3-year overall survival rate for patients treated with nivolumab was 51.2%, compared with 21.6% for those who received dacarbazine.
From the Journals
TKIs and immunotherapy hold promise for alveolar soft part sarcoma
Tyrosine kinase inhibitors and immune checkpoint inhibitors show encouraging results in the treatment of alveolar soft part sarcoma